| Basics |
Protagonist Therapeutics, Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
|
| IPO Date: |
August 11, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.88B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.53 | 2.88%
|
| Avg Daily Range (30 D): |
$0.73 | 1.64%
|
| Avg Daily Range (90 D): |
$0.96 | 2.16%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.47M |
| Avg Daily Volume (30 D): |
.62M |
| Avg Daily Volume (90 D): |
.8M |
| Trade Size |
| Avg Trade Size (Sh.): |
77 |
| Avg Trade Size (Sh.) (30 D): |
44 |
| Avg Trade Size (Sh.) (90 D): |
47 |
| Institutional Trades |
| Total Inst.Trades: |
2,590 |
| Avg Inst. Trade: |
$2.63M |
| Avg Inst. Trade (30 D): |
$4.09M |
| Avg Inst. Trade (90 D): |
$4.04M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.59M |
| Avg Closing Trade (30 D): |
$6.58M |
| Avg Closing Trade (90 D): |
$7.75M |
| Avg Closing Volume: |
144.53K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.19
|
$-.54
|
|
Diluted EPS
|
|
$-.19
|
$-.54
|
|
Revenue
|
$
|
$ 28.32M
|
$ 4.68M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -11.66M
|
$ -33.21M
|
|
Operating Income / Loss
|
$
|
$ -19.31M
|
$ -41.45M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 42.4M
|
$ -224.52M
|
|
PE Ratio
|
|
|
|
|
